6-Aminonicotinamide (standaard)

6-Aminonicotinamide, a potent antimetabolite of nicotinamide, is competitive NADP+-dependent enzyme glucose-6-phosphate dehydrogenase (G6PD) inhibitor (Ki=0.46 μM). 6-Aminonicotinamide resultis ATP depletion and synergizes with DNA-crosslinking chemotherapy agents, such as Cisplatin , in killing cancer cells[1][2][3][4].

329-89-5

12352005

H360

NADPH Oxidase

Metabolic Enzyme/Protease

Cancer

NC1=CC=C(C(N)=O)C=N1

C6H7N3O

137.14

P280-P405-P501

[1]Cheng J, et al. TRIM21 and PHLDA3 negatively regulate the crosstalk between the PI3K/AKT pathway and PPP metabolism. Nat Commun. 2020;11 (1) :1880. Published 2020 Apr 20.|[2]Almugadam SH, et al. Influence of 6-aminonicotinamide (6AN) on Leishmania promastigotes evaluated by metabolomics: Beyond the pentose phosphate pathway. Chem Biol Interact. 2018;294:167-177.|[3]Tsouko E, et al. Regulation of the pentose phosphate pathway by an androgen receptor-mTOR-mediated mechanism and its role in prostate cancer cell growth. Oncogenesis. 2014;3 (5) :e103. Published 2014 May 26.|[4]Koutcher JA, et al. Effect of 6-aminonicotinamide on the pentose phosphate pathway: 31P NMR and tumor growth delay studies. Magn Reson Med. 1996;36 (6) :887-892.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-W010342R/

Reference Standards